Alexander Cumbo - Net Worth and Insider Trading

Alexander Cumbo Net Worth

The estimated net worth of Alexander Cumbo is at least $2 Million dollars as of 2026-09-11. Alexander Cumbo is the President and CEO of Solid Biosciences Inc and owns about 235,405 shares of Solid Biosciences Inc (SLDB) stock worth over $2 Million. Alexander Cumbo is also the EVP, Chief Commercial Officer of Sarepta Therapeutics Inc and owns about 5,308 shares of Sarepta Therapeutics Inc (SRPT) stock worth over $109,239. Details can be seen in Alexander Cumbo's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Alexander Cumbo has not made any transactions after 2026-02-18 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Alexander Cumbo

Are these stocks worth buying? — GuruFocus analysis for each holding

- GF

SLDB Solid Biosciences Inc

95% of holdings · $2.1M

SRPT Sarepta Therapeutics Inc

5% of holdings · $109K

Alexander Cumbo Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Alexander Cumbo owns 6 companies in total, including Ra Pharmaceuticals Inc (RARX) , Sarepta Therapeutics Inc (SRPT) , and Verve Therapeutics Inc (VERV) among others .

Click here to see the complete history of Alexander Cumbo’s form 4 insider trades.

Insider Ownership Summary of Alexander Cumbo

Ticker	Company	Transaction Date	Type of Owner
RARX	Ra Pharmaceuticals Inc	2020-04-02	director
SRPT	Sarepta Therapeutics Inc	2019-12-13	VP & Head of Commercial
VERV	Verve Therapeutics Inc	2022-06-09	director
		2026-02-18	director & President and CEO
		2025-03-28	director
		2025-07-16	director

Alexander Cumbo Latest Holdings Summary

Alexander Cumbo currently owns a total of 2 stocks. Among these stocks, Alexander Cumbo owns 235,405 shares of Solid Biosciences Inc (SLDB) as of February 18, 2026, with a value of $2 Million and a weighting of 95.02%. Alexander Cumbo also owns 5,308 shares of Sarepta Therapeutics Inc (SRPT) as of December 13, 2019, with a value of $109,239 and a weighting of 4.98%.

Latest Holdings of Alexander Cumbo

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
SLDB	Solid Biosciences Inc	2026-02-18	235,405	8.85	2,083,334
SRPT	Sarepta Therapeutics Inc	2019-12-13	5,308	20.58	109,239

Holding Weightings of Alexander Cumbo

Alexander Cumbo Form 4 Trading Tracker

According to the SEC Form 4 filings, Alexander Cumbo has made a total of 6 transactions in Solid Biosciences Inc (SLDB) over the past 5 years, including 0 buys and 6 sells. The most-recent trade in Solid Biosciences Inc is the sale of 16,644 shares on February 18, 2026, which brought Alexander Cumbo around $96,868.

According to the SEC Form 4 filings, Alexander Cumbo has made a total of 0 transactions in Sarepta Therapeutics Inc (SRPT) over the past 5 years. The most-recent trade in Sarepta Therapeutics Inc is the sale of 42,000 shares on December 13, 2019, which brought Alexander Cumbo around $5 Million.

Insider Trading History of Alexander Cumbo

* The information on this page (including Insider Trading Shares, Share Changes, Cost, etc.) is sourced exclusively from Form 4 filings and does not incorporate any data from 13F or 13D/G filings. As a result, it may differ from the values shown on the Guru page.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Alexander Cumbo Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Get the full picture on these stocks

See GF Score, valuation, financials, and warning signs for every stock Alexander Cumbo owns.

- SLDB - SRPT

View SLDB Analysis

Alexander Cumbo Ownership Network

Ownership Network List of Alexander Cumbo

No Data

Ownership Network Relation of Alexander Cumbo

Alexander Cumbo Owned Company Details

What does Ra Pharmaceuticals Inc do?

Who are the key executives at Ra Pharmaceuticals Inc?

Alexander Cumbo is the director of Ra Pharmaceuticals Inc. Other key executives at Ra Pharmaceuticals Inc include Executive VP and CFO David Charles Lubner , director & 10 percent owner Rajeev M. Shah , and 10 percent owner New Enterprise Associates 13 Lp .

Ra Pharmaceuticals Inc (RARX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Ra Pharmaceuticals Inc (RARX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Ra Pharmaceuticals Inc (RARX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Ra Pharmaceuticals Inc (RARX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ra Pharmaceuticals Inc Insider Transactions

No Available Data

What does Sarepta Therapeutics Inc do?

Who are the key executives at Sarepta Therapeutics Inc?

Alexander Cumbo is the VP & Head of Commercial of Sarepta Therapeutics Inc. Other key executives at Sarepta Therapeutics Inc include director & Chief Executive Officer Michael Severino , Chief Financial Officer Ian Michael Estepan , and Chief Financial Officer Ryan Ho-yan Wong .

Sarepta Therapeutics Inc (SRPT) Insider Trades Summary

Over the past 18 months, Alexander Cumbo made no insider transaction in Sarepta Therapeutics Inc (SRPT). Other recent insider transactions involving Sarepta Therapeutics Inc (SRPT) include a net sale of 13,187 shares made by Ian Michael Estepan , a net sale of 7,239 shares made by Stephen Mayo , and a net sale of 2,491 shares made by Claude Nicaise .

In summary, during the past 3 months, insiders sold 0 shares of Sarepta Therapeutics Inc (SRPT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 22,917 shares of Sarepta Therapeutics Inc (SRPT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 22,917 shares.

Sarepta Therapeutics Inc (SRPT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sarepta Therapeutics Inc Insider Transactions

No Available Data

What does Verve Therapeutics Inc do?

Who are the key executives at Verve Therapeutics Inc?

Alexander Cumbo is the director of Verve Therapeutics Inc. Other key executives at Verve Therapeutics Inc include See Remarks Andrew D. Ashe , director & 10 percent owner & Chief Executive Officer Sekar Kathiresan , and Chief Administrative Officer Joan Nickerson .

Verve Therapeutics Inc (VERV) Insider Trades Summary

Over the past 18 months, Alexander Cumbo made no insider transaction in Verve Therapeutics Inc (VERV). Other recent insider transactions involving Verve Therapeutics Inc (VERV) include a net sale of 9,822 shares made by Sekar Kathiresan , a net sale of 3,350 shares made by Allison Dorval , and a net sale of 3,235 shares made by Jason Politi .

In summary, during the past 3 months, insiders sold 0 shares of Verve Therapeutics Inc (VERV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 24,054 shares of Verve Therapeutics Inc (VERV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 24,054 shares.

Verve Therapeutics Inc (VERV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Verve Therapeutics Inc Insider Transactions

No Available Data

What does Solid Biosciences Inc do?

Who are the key executives at Solid Biosciences Inc?

Alexander Cumbo is the director & President and CEO of Solid Biosciences Inc. Other key executives at Solid Biosciences Inc include See Remarks David T Howton , Chief Technology Officer Paul Herzich , and Chief Regulatory Officer Jessie Hanrahan .

Solid Biosciences Inc (SLDB) Insider Trades Summary

Over the past 18 months, Alexander Cumbo made 4 insider transaction in Solid Biosciences Inc (SLDB) with a net sale of 156,623. Other recent insider transactions involving Solid Biosciences Inc (SLDB) include a net sale of 14,385 shares made by Ilan Ganot , a net sale of 52,728 shares made by Kevin Tan , and a net sale of 47,500 shares made by Jessie Hanrahan .

In summary, during the past 3 months, insiders sold 0 shares of Solid Biosciences Inc (SLDB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 389,849 shares of Solid Biosciences Inc (SLDB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 389,849 shares.

Solid Biosciences Inc (SLDB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Solid Biosciences Inc Insider Transactions

No Available Data

What does Climb Bio Inc do?

Who are the key executives at Climb Bio Inc?

Alexander Cumbo is the director of Climb Bio Inc. Other key executives at Climb Bio Inc include director & President and CEO Aoife Brennan , director & 10 percent owner Ra Capital Healthcare Fund Lp , and Chief Financial Officer Susan Altschuller .

Climb Bio Inc (CLYM) Insider Trades Summary

Over the past 18 months, Alexander Cumbo made no insider transaction in Climb Bio Inc (CLYM). Other recent insider transactions involving Climb Bio Inc (CLYM) include a net purchase of 321,672 shares made by Ra Capital Healthcare Fund Lp , a net sale of 150,000 shares made by Stephen Basil Thomas , and a net sale of 51,520 shares made by Aoife Brennan .

In summary, during the past 3 months, insiders sold 30,902 shares of Climb Bio Inc (CLYM) in total and bought 0 shares, with a net sale of 30,902 shares. During the past 18 months, 203,961 shares of Climb Bio Inc (CLYM) were sold and 321,672 shares were bought by its insiders, resulting in a net purchase of 117,711 shares.

Climb Bio Inc (CLYM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Climb Bio Inc Insider Transactions

No Available Data

What does Vor Biopharma Inc do?

Who are the key executives at Vor Biopharma Inc?

Alexander Cumbo is the director of Vor Biopharma Inc. Other key executives at Vor Biopharma Inc include director & 10 percent owner Ra Capital Healthcare Fund Lp , Chief Medical Officer Jeremy Brett Sokolove , and 10 percent owner Tcg Crossover Gp Iii, Llc .

Vor Biopharma Inc (VOR) Insider Trades Summary

Over the past 18 months, Alexander Cumbo made no insider transaction in Vor Biopharma Inc (VOR). Other recent insider transactions involving Vor Biopharma Inc (VOR) include a net sale of 6,665,043 shares made by Reprogrammed Interchange Llc , and a net sale of 4,205,765 shares made by Ra Capital Healthcare Fund Lp .

In summary, during the past 3 months, insiders sold 213 shares of Vor Biopharma Inc (VOR) in total and bought 0 shares, with a net sale of 213 shares. During the past 18 months, 4,987,561 shares of Vor Biopharma Inc (VOR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 4,987,561 shares.

Vor Biopharma Inc (VOR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Vor Biopharma Inc Insider Transactions

No Available Data

Alexander Cumbo Mailing Address

Above is the net worth, insider trading, and ownership report for Alexander Cumbo. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Alexander Cumbo's mailing address is: Cambridge Ma 02142.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.